Literature DB >> 32435361

Chimeric Peptidomimetics of SOCS 3 Able to Interact with JAK2 as Anti-inflammatory Compounds.

Sara La Manna1,2, Laura Lopez-Sanz2,3, Flavia Anna Mercurio4, Sara Fortuna5, Marilisa Leone4, Carmen Gomez-Guerrero2,3, Daniela Marasco1.   

Abstract

The immunomodulatory effects of Suppressor of Cytokine Signaling (SOCS) proteins, that control the JAK/STAT pathway, indicate them as attractive candidates for immunotherapies. Recombinant SOCS3 protein suppresses the effects of inflammation, and its deletion in neurons or in immune cells increases pathological blood vessels growth. Recently, on the basis of the structure of the ternary complex among SOCS3, JAK2, and gp130, we focused on SOCS3 interfacing regions and designed several interfering peptides (IPs) that were able to mimic SOCS3 biological role in triple negative breast cancer (TNBC) models. Herein, to explore other protein regions involved in JAK2 recognition, several new chimeric peptides connecting noncontiguous SOCS3 regions and including a strongly aromatic fragment were investigated. Their ability to recognize the catalytic domain of JAK2 was evaluated through MST (microscale thermophoresis), and the most promising compound, named KIRCONG chim, exhibited a low micromolar value for dissociation constant. The conformational features of chimeric peptides were analyzed through circular dichroism and NMR spectroscopies, and their anti-inflammatory effects were assessed in cell cultures. Overall data suggest the importance of aromatic contribution in the recognition of JAK2 and that SOCS3 peptidomimetics could be endowed with a therapeutic potential in diseases with activated inflammatory cytokines.
Copyright © 2020 American Chemical Society.

Entities:  

Year:  2020        PMID: 32435361      PMCID: PMC7236031          DOI: 10.1021/acsmedchemlett.9b00664

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  55 in total

Review 1.  Targeting "Undruggable" Proteins: Design of Synthetic Cyclopeptides.

Authors:  Anna Russo; Carmela Aiello; Paolo Grieco; Daniela Marasco
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

2.  Alveolar macrophage secretion of vesicular SOCS3 represents a platform for lung cancer therapeutics.

Authors:  Jennifer M Speth; Loka R Penke; Joseph D Bazzill; Kyung Soo Park; Rafael Gil de Rubio; Daniel J Schneider; Hideyasu Ouchi; James J Moon; Venkateshwar G Keshamouni; Rachel L Zemans; Vibha N Lama; Douglas A Arenberg; Marc Peters-Golden
Journal:  JCI Insight       Date:  2019-10-17

3.  Suppressor of Cytokine Signaling-1 Peptidomimetic Limits Progression of Diabetic Nephropathy.

Authors:  Carlota Recio; Iolanda Lazaro; Ainhoa Oguiza; Laura Lopez-Sanz; Susana Bernal; Julia Blanco; Jesus Egido; Carmen Gomez-Guerrero
Journal:  J Am Soc Nephrol       Date:  2016-09-08       Impact factor: 10.121

4.  Suppressors of cytokine signaling abrogate diabetic nephropathy.

Authors:  Guadalupe Ortiz-Muñoz; Virginia Lopez-Parra; Oscar Lopez-Franco; Paula Fernandez-Vizarra; Beñat Mallavia; Claudio Flores; Ana Sanz; Julia Blanco; Sergio Mezzano; Alberto Ortiz; Jesus Egido; Carmen Gomez-Guerrero
Journal:  J Am Soc Nephrol       Date:  2010-02-25       Impact factor: 10.121

5.  Structure-activity studies of peptidomimetics based on kinase-inhibitory region of suppressors of cytokine signaling 1.

Authors:  Sara La Manna; Laura Lopez-Sanz; Marilisa Leone; Paola Brandi; Pasqualina Liana Scognamiglio; Giancarlo Morelli; Ettore Novellino; Carmen Gomez-Guerrero; Daniela Marasco
Journal:  Biopolymers       Date:  2017-11-20       Impact factor: 2.505

Review 6.  The roles of SOCS3 and STAT3 in bacterial infection and inflammatory diseases.

Authors:  Yu Gao; Honglei Zhao; Peng Wang; Jun Wang; Lili Zou
Journal:  Scand J Immunol       Date:  2018-12       Impact factor: 3.487

7.  SOCS1 Mimetic Peptide Suppresses Chronic Intraocular Inflammatory Disease (Uveitis).

Authors:  Chang He; Cheng-Rong Yu; Mary J Mattapallil; Lin Sun; Joseph Larkin Iii; Charles E Egwuagu
Journal:  Mediators Inflamm       Date:  2016-09-15       Impact factor: 4.711

8.  Protective effects of SOCS3 overexpression in high glucose‑induced lung epithelial cell injury through the JAK2/STAT3 pathway.

Authors:  Wei-Na Duan; Zhong-Yuan Xia; Min Liu; Qian Sun; Shao-Qing Lei; Xiao-Jing Wu; Qing-Tao Meng; Yan Leng
Journal:  Mol Med Rep       Date:  2017-07-06       Impact factor: 2.952

9.  SOCS1-Derived Peptide Administered by Eye Drops Prevents Retinal Neuroinflammation and Vascular Leakage in Experimental Diabetes.

Authors:  Cristina Hernández; Patricia Bogdanov; Carmen Gómez-Guerrero; Joel Sampedro; Cristina Solà-Adell; Carmen Espejo; Marta García-Ramírez; Ignacio Prieto; Jesús Egido; Rafael Simó
Journal:  Int J Mol Sci       Date:  2019-07-24       Impact factor: 5.923

Review 10.  SOCS, inflammation, and cancer.

Authors:  Kyoko Inagaki-Ohara; Taisuke Kondo; Minako Ito; Akihiko Yoshimura
Journal:  JAKSTAT       Date:  2013-08-15
View more
  4 in total

Review 1.  The Suppressor of Cytokine Signalling family of proteins and their potential impact on COVID-19 disease progression.

Authors:  Zheng Yao Low; Ashley Jia Wen Yip; Vincent T K Chow; Sunil K Lal
Journal:  Rev Med Virol       Date:  2021-09-21       Impact factor: 11.043

2.  Structure-Activity Relationship Investigations of Novel Constrained Chimeric Peptidomimetics of SOCS3 Protein Targeting JAK2.

Authors:  Sara La Manna; Marilisa Leone; Flavia Anna Mercurio; Daniele Florio; Daniela Marasco
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-09

3.  Computational Evolution of Beta-2-Microglobulin Binding Peptides for Nanopatterned Surface Sensors.

Authors:  Abimbola Feyisara Adedeji Olulana; Miguel A Soler; Martina Lotteri; Hendrik Vondracek; Loredana Casalis; Daniela Marasco; Matteo Castronovo; Sara Fortuna
Journal:  Int J Mol Sci       Date:  2021-01-15       Impact factor: 5.923

Review 4.  Proteomimetics of Natural Regulators of JAK-STAT Pathway: Novel Therapeutic Perspectives.

Authors:  Sara La Manna; Ilaria De Benedictis; Daniela Marasco
Journal:  Front Mol Biosci       Date:  2022-01-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.